ALK.TCR-T #2

About ALKemist Bio

ALKemist Bio is a private, preclinical-stage biotech company founded in 2018 and based in Milan, Italy. It is pioneering a novel, dual-platform approach to cell therapy, developing both CAR-T and TCR-T treatments specifically engineered to target the ALK oncogene across various solid tumors, including neuroblastoma and NSCLC. The company is built on foundational research from Professor Roberto Chiarle and is backed by a €6.9M investment round, positioning it to address a significant unmet need in oncology for patients with ALK-driven cancers resistant to standard therapies.

Therapeutic Areas

Other ALK+ NSCLC Drugs